MODERN POSSIBILITIES OF MOLECULAR ONCOLOGY: CIRCULATING TUMOR CELLS

DOI: https://doi.org/None

O.I. Kit, Yu.A. Gevorkyan, N.V. Soldatkina, I.A. Novikova Rostov Research Oncological Institute, 14 line, 63, Rostov-on-Don, 344067, Russian Federation

The purpose of the study was to analyze publications on circulating tumor cells and to conduct our own research. Detection of circulating tumor cells was made in 60 patients with colorectal cancer and resectable metastatic liver lesion Т2-4N0-1M1 on the tenth day after the surgery using the CellSearchTM system by Veridex, the data obtained were analyzed. The results showed that the study of circulating tumor cells can greatly contribute to the development of fundamental oncology, and the cells can play a significant clinical role as a prognostic tumor marker of a new generation, influencing the choice of cancer treatment and controlling its efficiency.
Keywords: 
circulating tumor cells, advanced colorectal cancer

Список литературы: 
  1. Siegel R., Waud E., Brawley O., Jemal A. Cancer statistics-2011. CA Cancer J. Clin. 2011; 61: 212–36.
  2. Kovalev A.A. Onkohirurgiya v postgenomnuyu e`ru. Zhurnal onkologii. Hirurgiya. 2012; 3.[Kovalev A.A. Oncosurgery in postgenome era. J. of Oncology. Surgery. 2012; 3 (in Russian)]
  3. El`cheva I.A. Analiz molekulyarno-geneticheskih izmeneniy pri razlichnyh tipah raka yaichnikov. Dis. … kand. med. nauk. Moskva. 2000.[Elcheva I.A. Analysis of molecular genetic changes in ovarian cancer of different types. PhD dissertation. Moscow. 2000 (in Russian)]
  4. Semiglazov V.F., Semiglazov V.V., Dashyan G.A. Strategiya lecheniya raka molochnoy zhelezy, osnovannaya na vydelenii biologicheskih podtipov. Vrach. 2011; 12: 28–34.[Semiglazov V.F., Semiglazov V.V., Dashyan G.A. Strategy of treatment for breast cancer based on classification of biological subtypes. Vrach. 2011; 12: 28–34 (in Russian)]
  5. Gulyaeva Yu.V., Smolyakova R.M. Molekulyarno-geneticheskoe testirovanie pri nasledstvennom nepolipoznom kolorektal`nom rake. Onkologicheskiy zhurnal. 2013; 7, 2 (26): 86–92.[Gulyaeva Yu.V., Smolyakova R.M. Molecular genetic testing in hereditary nonpolyposis colorectal cancer. Onkologicheskiy Zhurnal. 2013; 7, 2 (26): 86–92 (in Russian)]
  6. Kostin P.A., Zaharzhevskaya N.B., Generozov E`.V. Vyyavlenie gipermetilirovaniya genov CDH1, SEPT9,HLTF i ALX4 i analiz ego diagnosticheskogo znacheniya pri opuholyah tolstoy kishki. Voprosy onkologii. 2010; 56 (2): 162–8.[Kostin P.A., Zakharzhevskaya N.B., Generozov E.V. Detection of hypermethylation of CDH1, SEPT9, HLTF and ALX4 genes and analysis of its diagnostic value in tumors of the colon. Voprosy onkologii. 2010; 56 (2): 162–8 (in Russian)]
  7. Kushlinskiy N.E., Isakov V.A., Delektorskaya V.V. Kolorektal`nyy rak. Opuholevye markery i molekulyarno-geneticheskie metody diagnostiki. Sibirskiy onkologicheskiy zhurnal. 2004; 2–3: 134–48.[Kushlinskiy N.E., Isakov V.A., Delektorskaya V.V. Colorectal cancer. Tumor markers and molecular genetic diagnostic methods. Sibirskiy Onkologicheskiy Zhurnal. 2004; 2–3: 134–48 (in Russian)]
  8. Nemcova M.V., Mihaylenko D.S., Kekeeva T.V. Molekulyarno-geneticheskie markery v onkourologii. Molekulyarnaya medicina. 2007; 3: 43–54.[Nemtsova M.V., Mikhaylenko D.S., Kekeyeva T.V. et al. Molecular genetic markers in oncourology. Molekulyarnaya Meditsina. 2007; 3: 43–54 (in Russian)]
  9. Lague M.N. Proteomic profiling of a mouse model for ovarian granulosa cell tumor identifies VCP as a highly sensitive serum tumor marker in several human cancers. PLoS One. 2012; 7: 424.
  10. Dezhenkova L.G., Cvetkov V.B., Shtil` A.A. Ingibitory topoizomeraz I i II: himicheskaya struktura, mehanizmy deystviya i rol` v himioterapii opuholey. Uspehi himii. 2013; 83 (1): 82–94.[Dezhenkova L.G., Tsvetkov V.B., Shtil A.A. Topoisomerase I and II inhibitors: chemical structure, mechanisms of action and role in cancer chemotherapy. Russian Chemical Reviews. 2013; Vol. 83, 1: 82–94 (in Russian)]
  11. Imyanitov E.N., Moiseenko V.M. Primenenie molekulyarno-geneticheskogo analiza dlya vybora protivoopuholevoy citostaticheskoy terapii. Onkogematologiya. 2007; 3: 4–8.[Imyanitov E.N., Moiseenko V.M. Application of molecular genetic analysis for choosing antitumor cytostatic therapy. Oncohematology. 2007; 3: 4–8 (in Russian)]
  12. Abramov M.E., Shvarova A.V., Stepanova E.V. Personificirovannaya himioterapiya: markery predskazaniya toksichnosti protivoopuholevyh preparatov. Sarkomy kostey, myagkih tkaney i opuholi kozhi. 2011; 4: 73–6.[Abramov M.E., Shvarova A.V., Stepanova E.V. Personalized chemotherapy: markers for predicting the toxicity of anticancer drugs. Sarkomy kostey, myagkikh tkaney i opukholi kozhi. 2011; 4: 73–6 (in Russian)]
  13. Salts L.B., Clarke S., Diaz-Rubio E. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J. Clin. Oncol. 2008; 26: 2013–9.
  14. Tol J., Koopman M., Cats A. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N. Engl. J. Med. 2009; 360: 563–72.
  15. Shvarcburd P.M. Stvolovye kletki v razvitii raka i predrakovogo mikrookruzheniya. Molekulyarnaya medicina. 2007; 4: 3–8.[Shvartsburd P.M. Stem cells in the development of cancer and precancerous microenvironment. Molekulyarnaya Meditsina. 2007; 4: 3–8 (in Russian)]
  16. Chissov V.I., Sergeeva H.S., Sviridova I.K., Pelevina I.I. Stvolovye (klonogennye) kletki zlokachestvennyh opuholey: vozvrashhayas` k poluchennym dannym. Rossiyskiy bioterapevticheskiy zhurnal. 2006; 5, 2: 7–12.[Chissov V.I., Sergeeva N.S., Sviridova I.K., Pelevina I.I. Stem (clonogenic) sells: back to the received data. Rossiysky Bioterapevtichesky Zhurnal. 2006; 5, 2: 7–12 (in Russian)]
  17. Tupicyn N.N. Biologicheskoe i klinicheskoe znachenie cirkuliruyushhih i disseminirovannyh rakovyh kletok. Immunologiya gemopoe`za. 2012; 10, 2: 35–45.[Tupitsyn N.N. Biological and clinical significance of circulating and disseminated cancer cells. Haematopoiesis Immunology. 2012; 10, 2: 35–45 (in Russian)]
  18. Shah M., Allergucci C. Keeping an open mind: highlights and controversies of the breast cancer stem cell theory. Breast cancer: targets and therapy. 2012; 4: 155–66.
  19. Bednarz-Knoll N., Alix-Panabieres C., Pantel K. Clinical relevance and biology of circulating tumor cells. Breast Cancer Res. 2011; 13: 228–38.
  20. Lu X., Mu E., Wei Y. VCAM-1 promotes osteolytic expansion of indolent bone micrometastasis of breast cancer by engaging a4b1-positive osteoclast progenitors. Cancer Cell. 2011; 20: 701–14.
  21. Christophanilly M., Budd G.T., Ellis M.J. Circulating Tumor Cells. Disease Progression and Survival in Metastatic Breast Cancer. N. Engl. J. Med. 2004; 351: 781–91.
  22. Cohen S.J., Punt C.J., Iannotti N. Relationship of circulating tumor cells to tumor response, progression-free survival and overall survival in patients with metastatic colorectal cancer. J. Clin. Oncol. 2008; 26: 3213–21.
  23. De Bono J.S., Scher H.I., Montgomery R.B. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistantprostate cancer. Clin. Cancer Research. 2008; 14: 6302–9.
  24. Bzhadug O.B., Tjuliandin S.A., Grivtsova L.Yu. The prognostic value of circulating tumor cells in blood of patients with advanced breast cancer. Haematopoiesis Immunology. 2007; 4: 73–101.
  25. Jiao O. J. Clin. Oncol. 2009; 27 (36): 6160–5.
  26. Alix-Panabieres C., Pantel K. Detection and characterization of disseminating cancer cells in patients with solid epithelial malignancies. Haematopoiesis Immunology. 2012; 10 (1): 79–93.
  27. Janni W., Vogl F.D., Wiedswang G. Persistence of disseminated tumor cells in the bone marrow of breast cancer patients predicts increased risk for relapse – a European pooled study. Clin. Cancer. Res. 2011; 17: 2967–76.
  28. Bednarz-Knoll N., Alix-Panabieres C., Pantel K. Plasticity of disseminating cancer cells in patients with epithelial malignancies. Cancer Metastasis Rev. 2012; 3–4: 673–87.